• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - chemotherapy
Tag:

chemotherapy

Tech

New Spatial Map Uncovers Bladder Cancer Treatment Vulnerabilities

by Chief Editor June 18, 2026
written by Chief Editor

Researchers at The University of Texas MD Anderson Cancer Center have mapped the spatial architecture of muscle-invasive bladder cancer, identifying how tumor cell states and immune environments interact within specific regions of a tumor. Published in Cancer Discovery, the study reveals that bladder cancer is not a uniform disease, but a complex landscape where luminal and basal-like cell states coexist, offering a new framework for precision therapy selection.

How does the spatial map change our understanding of bladder cancer?

Traditional molecular subtyping has historically classified bladder cancer into two categories: luminal or basal. However, the MD Anderson team found this binary model fails to capture the full picture. According to Linghua Wang, M.D., Ph.D., the study demonstrates that these distinct cell states exist within the same tumor in highly organized, physical patterns.

How does the spatial map change our understanding of bladder cancer?

By integrating spatial transcriptomics from 22 pretreatment tumors with whole-exome and single-cell sequencing, researchers identified a continuous differentiation axis. Luminal-like cells, which are enriched for markers like FGFR3 and NECTIN4, typically occupy the tumor core. Conversely, basal-like cells—characterized by EGFR signaling and higher chromosomal instability—predominate near the invasive margins of the tumor.

Did you know?
The research team validated these spatial findings across more than 3,000 independent bladder cancer tumors, confirming that the physical location of cells is a reliable indicator of their biological behavior and aggressiveness.

What are the implications for future treatment strategies?

The study suggests that future clinical approaches should move away from treating bladder cancer as a uniform entity. Jianjun Gao, M.D., Ph.D., professor of Genitourinary Medical Oncology, notes that effective care may require targeting both the luminal and basal components within the same patient.

What are the implications for future treatment strategies?
  • NECTIN4-targeted therapies: Because luminal regions show high NECTIN4 expression, drugs like enfortumab vedotin are better suited for these specific tumor cores.
  • Chemotherapy and immunotherapy: Basal-like margins exhibit higher immune infiltration, suggesting these regions may respond more favorably to chemotherapy or immunotherapy-based regimens.

By identifying these lineage-specific vulnerabilities, clinicians could eventually use spatial data to sequence therapies, hitting distinct tumor compartments with the most effective agents for that specific region.

What happens next in clinical research?

The next phase of research focuses on validating these findings in larger, prospective clinical cohorts. While the current data provides a roadmap for pretreatment tumor analysis, researchers must now determine how these spatial architectures shift over time during treatment.

Bladder Cancer Breakthroughs 2025: New Treatments & Bladder-Sparing Advances

Post-treatment samples will be critical to understanding if therapy reshapes the tumor’s “map” or if residual cells adopt new states. According to the MD Anderson team, this longitudinal data is essential for transitioning from static snapshots to dynamic, adaptive treatment plans that account for tumor evolution.

Pro Tip:
If you are tracking advancements in oncology, look for clinical trials that incorporate spatial transcriptomics. These studies are increasingly used to explain why patients with similar genetic profiles often experience different outcomes when receiving the same standard-of-care drugs.

Frequently Asked Questions

Why do some bladder cancer patients respond better to treatment than others?
According to MD Anderson researchers, varying responses are likely linked to the spatial organization of the tumor. Because tumors contain diverse cell states in different regions, a drug that works on the tumor core may not be effective at the invasive margin.

Frequently Asked Questions

What is the difference between luminal and basal-like tumor cells?
Luminal cells are typically found in the tumor core and express FGFR3 and NECTIN4. Basal-like cells are found at the invasive margins, showing higher EGFR signaling and increased immune infiltration.

Can spatial mapping be used in clinical practice today?
Not yet. The current findings provide a framework for future biomarker development. Prospective clinical trials are required to validate these findings before they become part of standard diagnostic or treatment protocols.


Are you interested in the latest breakthroughs in cancer research? Subscribe to our newsletter for updates on precision oncology and emerging therapeutic technologies.

June 18, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

New Medicaid Guidance Puts Patient Coverage at Risk

by Chief Editor June 11, 2026
written by Chief Editor

New Medicaid work requirements mandated by the federal government are set to take effect next year, creating significant uncertainty for millions of enrollees who rely on the program for life-saving medical care. Under new guidance from the Centers for Medicare and Medicaid Services (CMS), participants will be required to document 80 hours of monthly work, community service, or education to maintain eligibility. While exemptions exist for those deemed medically frail, the administration’s narrow definition—requiring proof that a condition “significantly impairs” the ability to work—has sparked concerns from healthcare providers and state officials about potential coverage losses and increased bureaucratic burdens for the nation’s sickest patients.

How Will the New “Medical Frailty” Definition Affect Patients?

The updated CMS guidance requires that individuals seeking a “medically frail” exemption must prove their condition prevents them from meeting work requirements. According to the federal rule, a diagnosis alone is insufficient. Patients must provide documentation that their symptoms “significantly impair” their ability to fulfill the 80-hour monthly mandate. Adrianna McIntyre, a professor at the Harvard University school of public health, stated that this policy shift will likely force the sickest patients to navigate complex, time-consuming paperwork, which she suggests will lead to people “needlessly losing coverage.” For patients like DeAnna Brandon, a multiple myeloma survivor, the fear is that an inability to secure formal medical certification could jeopardize the twice-monthly chemotherapy treatments keeping her cancer in remission.

View this post on Instagram about Associated Press, Harvard University
From Instagram — related to Associated Press, Harvard University
Did you know?

While the federal government has allocated $200 million to assist states with implementation, an analysis by the Associated Press suggests the actual costs for technology upgrades and additional staffing will likely exceed $1 billion.

Why Are States Struggling to Implement the New Rules?

State Medicaid agencies are facing a technical and logistical challenge as they prepare for a January kickoff. Many states originally intended to use existing claims data to automatically exempt vulnerable enrollees. However, CMS administrator Dr. Mehmet Oz confirmed to the Associated Press that the agency will not allow states to “categorically exclude” individuals based solely on a diagnosis. This leaves officials in a difficult position. Kinda Serafi, a partner at the legal and consulting firm Manatt Health, noted that states are being asked to make eligibility determinations using information—specifically data proving “significant impairment”—that does not currently exist in their systems.

Why Are States Struggling to Implement the New Rules?

What Is the Government’s Stated Goal for These Requirements?

Proponents of the policy, including the Trump administration, argue that work requirements are necessary to preserve Medicaid for those with the greatest need. Dr. Mehmet Oz cited a report from the American Enterprise Institute, a conservative think tank, which claimed that able-bodied Medicaid enrollees spend an average of 6.1 hours a day “watching TV or just hanging out.” Oz described the new requirements as a “commonsense” approach to discourage government dependency. Conversely, critics, including Democratic lawmakers and patient advocates, characterize the move as an attack on the healthcare safety net, arguing that the policy ignores the reality of those living with chronic conditions who are not yet qualified for federal disability benefits.

Adrianna McIntyre & Yevgeniy Feyman [The Good Fight round 2]
Pro Tip: Documentation Matters

If you are a Medicaid enrollee with a chronic health condition, begin discussing the new requirements with your primary care provider now. Ask if they are prepared to provide the specific clinical documentation required to certify that your condition limits your ability to work, as some providers may be hesitant or unable to provide such certifications.

Frequently Asked Questions

  • Who is affected by the new Medicaid work requirements?
    Expansion enrollees aged 19 to 64 are subject to the new rules, which require 80 hours of work, community service, or education per month.
  • Are there exemptions for people with disabilities?
    Yes, exemptions exist for those classified as “medically frail,” but the new federal rule requires proof that the condition significantly impairs the ability to work, rather than relying on a diagnosis alone.
  • What happens if I cannot meet the requirements?
    Failure to meet the work mandate or provide valid exemption documentation could result in the loss of Medicaid health insurance coverage.
  • Do I need to prove my status immediately?
    The government allows for self-attestation in 2027 and 2028, but official verification through claims data or medical documentation will be required during the renewal process in 2028.

Have you or a family member been impacted by changes to Medicaid eligibility? Share your experience in the comments below or subscribe to our health policy newsletter for ongoing updates as states roll out these new requirements.

Frequently Asked Questions

June 11, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Gene Test Identifies Breast Cancer Patients Who Can Safely Skip Chemotherapy

by Chief Editor June 9, 2026
written by Chief Editor

A genomic test can identify many breast cancer patients who can safely forgo chemotherapy without increasing their risk of recurrence, according to results from the international OPTIMA trial presented at the 2026 American Society of Clinical Oncology meeting. Researchers found that patients aged 40 and over with hormone-sensitive tumors and a low Prosigna test score achieved five-year survival rates comparable to those who received chemotherapy, effectively sparing thousands of patients from unnecessary treatment-related toxicity.

How does the Prosigna test determine treatment?

The Prosigna test measures the activity of genes involved in breast cancer growth using tissue samples from surgery or diagnostic biopsies, according to the OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) research team. By analyzing these biological markers, clinicians can distinguish between tumors that require aggressive systemic treatment and those that respond sufficiently to hormone therapy alone. Lead investigator Professor Rob Stein of the University College London Cancer Institute states that the test allows medical teams to shift away from relying solely on traditional clinical features, such as tumor size or lymph node involvement, toward a model driven by tumor biology.

How does the Prosigna test determine treatment?
Did you know?
The OPTIMA trial included 4,429 patients across the UK, Norway, Sweden, Australia, New Zealand, and Thailand. Unlike previous studies that focused heavily on postmenopausal women with limited lymph node involvement, this trial included premenopausal women and those with more extensive disease.

What were the survival outcomes for patients?

Data from the trial shows that 68% of participants received a low Prosigna score, indicating a low risk of recurrence. For this specific group, the five-year survival rate was 94.9% for those who received chemotherapy and 95.1% for those who did not. According to the study’s statistical analysis, at most 2% of patients with a low score would see any benefit from chemotherapy, suggesting the treatment provides little to no additional protection for the vast majority of this population. Professor Iain MacPherson of the University of Glasgow notes that these findings provide robust, practice-changing evidence that chemotherapy use can be safely reduced.

What were the survival outcomes for patients?

Case Study: A patient’s experience with genomic testing

Karen Bonham, a 64-year-old speech and language therapist from Cardiff, was diagnosed with hormone-sensitive breast cancer in 2017. Despite standard clinical guidelines suggesting chemotherapy for her specific diagnosis—which included two affected lymph nodes—the Prosigna test results arrived just days before her scheduled treatment. Because her test indicated a low score, Bonham was assigned to the trial’s test-directed group. She avoided chemotherapy entirely, opting instead for radiotherapy and hormone therapy. Almost nine years later, Bonham remains cancer-free, attributing her quality of life to the ability to receive targeted, appropriate treatment rather than a one-size-fits-all regimen.

The OPTIMA Clinical Trial

What is the future of genomic testing in the NHS?

Healthcare bodies, including the National Institute for Health and Care Excellence (NICE), are expected to use these findings to evaluate wider access to Prosigna testing. By demonstrating the cost-effectiveness of test-directed treatment, the trial provides a pathway for the National Health Service (NHS) to reduce unnecessary chemotherapy for an estimated 5,000 patients annually. While the current results are comprehensive, researchers noted that it is not yet known if these findings apply to patients under the age of 40. The next phase of the trial is designed to generate data specifically for this younger demographic.

Pro Tip:
If you or a loved one are facing a breast cancer diagnosis, ask your oncologist if genomic testing is appropriate for your specific tumor profile. Understanding the biological activity of the cancer can often help patients and doctors make more informed decisions about the necessity of systemic therapies.

Frequently Asked Questions

  • Who is eligible for the Prosigna test? The OPTIMA trial results apply to patients aged 40 and older with hormone-sensitive breast cancer.
  • Does the test work for patients with lymph node involvement? Yes. The trial successfully demonstrated that outcomes were similar regardless of the number of affected lymph nodes.
  • Is chemotherapy always necessary for breast cancer? No. According to the OPTIMA trial, many patients with low genomic scores can safely avoid chemotherapy without compromising their survival outcomes.

Have you or a family member been affected by breast cancer treatment decisions? Share your thoughts in the comments below or subscribe to our health newsletter for the latest updates on oncology research and personalized medicine.

June 9, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Cancer Survivors Face Employment and Social Hurdles Post-Recovery

by Chief Editor June 6, 2026
written by Chief Editor

Beyond the Diagnosis: The New Frontier of Survivorship

For millions, the final round of chemotherapy is hailed as a victory. But as medical advancements continue to increase survival rates, a new, complex reality is emerging: the “second diagnosis.” This isn’t a medical recurrence, but a social and economic one—the struggle to reintegrate into a workforce that often views survivors through a lens of stigma and outdated stereotypes.

Did You Know? According to recent oncology studies, cancer survivors often report that the psychological and professional hurdles faced after treatment are more daunting than the medical protocols themselves.

The “Survivor Penalty” in the Modern Workplace

The modern professional landscape is built on a culture of “always-on” productivity. For a survivor returning to the office, this environment can feel hostile. Survivors like Tanuja Behera, who battled gastric cancer, often find that colleagues mistake their need for adjustment as a lack of capability.

The trend is clear: we are seeing a rise in what experts call the “survivor penalty.” This includes:

  • Career Interruption: Gaps in employment are often unfairly flagged by automated recruitment software.
  • Implicit Bias: Managers may unconsciously assign less critical projects to survivors, fearing they cannot handle “deadlines.”
  • Financial Strain: The depletion of savings during treatment often forces survivors into immediate, high-pressure roles, exacerbating physical fatigue.

Reframing Resilience: Why Survivors Make Exceptional Employees

Clinical psychologists and workplace experts are pushing back against the narrative of “weakness.” In fact, the data suggests the opposite. Survivors often return to the workforce with a heightened sense of emotional intelligence, discipline, and long-term perspective.

I discovered that I had uterine cancer by accident – Ms. Tanuja Malde #celebratinglife
Pro Tip for Employers: Implement “Return-to-Work” (RTW) programs that offer phased re-entry. Flexibility isn’t just a perk; it’s a strategy to retain top-tier talent who have proven their ability to overcome extreme adversity.

Shifting Towards Inclusive Policy

The future of survivorship lies in legislative and corporate policy. Advocates are now calling for structured protocols that protect survivors from discrimination. Much like the Americans with Disabilities Act (ADA) standards, global labor markets are beginning to explore “cancer-inclusive” hiring practices that normalize flexible hours and remote options for those recovering from chronic illness.

The Rise of Psycho-Oncology Rehabilitation

Hospitals are no longer just treating the tumor; they are treating the person. We are witnessing a significant increase in demand for post-treatment counseling. Rehabilitation is moving beyond physical therapy to encompass:

The Rise of Psycho-Oncology Rehabilitation
Career Counseling
  • Cognitive Behavioral Therapy (CBT): To manage the “fear of recurrence” (FCR).
  • Career Counseling: Helping survivors navigate the transition back into high-demand roles.
  • Support Networks: Peer-to-peer mentorship programs that connect survivors with industry veterans who have successfully navigated the same path.

Frequently Asked Questions

Q: How can I disclose my cancer history during an interview?
A: You are not legally required to disclose your medical history. Focus on your current capabilities and the skills you bring to the role. If you need accommodations, wait until you have a job offer to discuss them with HR.

Q: What is the most important trait for a returning survivor?
A: Self-advocacy. Communicating your needs—such as flexible start times or ergonomic setups—is a professional necessity, not a sign of weakness.


Join the Conversation: Have you or a loved one navigated the transition back to work after a serious health challenge? What policy changes would you like to see in your industry? Subscribe to our newsletter for more insights on workplace wellness or share your story in the comments below.

June 6, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Fertility Preservation Before Breast Cancer: My Personal Journey

by Chief Editor June 3, 2026
written by Chief Editor

A cancer diagnosis at any age is life-altering, but for young women, it often triggers a secondary, urgent crisis: the sudden collision of medical necessity and reproductive autonomy. When time is compressed into a 30-minute window, the decision to undergo fertility preservation—often while grappling with the physical and emotional toll of surgery and impending treatment—is a profound act of faith in a future that feels increasingly fragile.

The Paradox of Planning for a Future You Can’t Guarantee

The experience of “onco-fertility”—the intersection of oncology and reproductive medicine—is a stark reminder that motherhood is inherently an act of forward-thinking. It requires a belief in a future self and a future child. For many facing a health crisis, the choice to freeze eggs or embryos isn’t just about biological insurance; it is a vital reclamation of agency.

Medical experts emphasize that fertility is the natural capability to reproduce, but for those facing life-limiting illnesses, this capability is often under siege. Modern medicine is increasingly prioritizing “fertility preservation” as a standard part of cancer care protocols, recognizing that the emotional health of a patient is deeply tied to their future reproductive options.

Pro Tip: If you are facing a medical diagnosis that may impact your reproductive health, ask your oncology team for an immediate referral to a reproductive endocrinologist. Timing is critical, and many clinics now offer expedited protocols for patients with time-sensitive needs.

Advancements in Fertility Preservation

The landscape of reproductive technology is shifting rapidly. While traditional IVF has been the gold standard, new techniques are making preservation more accessible. We are seeing a rise in:

  • Ovarian Tissue Cryopreservation: A breakthrough for patients who cannot wait for the weeks required for hormonal stimulation.
  • Improved Vitrification: Modern “flash-freezing” techniques have significantly increased the survival rate of eggs and embryos compared to older “slow-freeze” methods.

According to the American Pregnancy Association, understanding your reproductive options early is the best way to maintain control over your biological future. Even for those not facing a medical crisis, the rise in elective egg freezing reflects a broader societal shift toward delaying parenthood and prioritizing “fertility autonomy.”

The Psychological Weight of Reproductive Decisions

The decision to pursue fertility preservation is rarely just medical; it is deeply psychological. It forces a patient to confront their mortality while simultaneously planning for life. As one patient noted, it is about giving a “future self a chance.”

Fertility Preservation in Breast Cancer Patients
Did you know? While many people believe fertility is solely about the egg, successful conception requires a complex interplay of hormones, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), as well as a receptive uterine environment, as detailed in current reproductive health guides.

Frequently Asked Questions

What is the difference between fertility and fecundity?
In medical and demographic terms, fertility refers to the actual production of offspring, while fecundity refers to the physiological potential or capability to reproduce.
How long does the fertility preservation process take?
A standard cycle typically involves about two weeks of hormonal stimulation followed by an egg retrieval procedure. However, “emergency” protocols can sometimes be expedited depending on the patient’s medical timeline.
Is it too late to consider fertility preservation after a diagnosis?
Not necessarily. While timing is vital, consult with a fertility specialist immediately. Even with a diagnosis, there may be options to protect your future reproductive health.

Taking Control of Your Narrative

Whether you are navigating a medical challenge or simply planning for a future family, being informed is your greatest asset. Fertility is not just a biological metric; it is a personal journey that deserves careful thought and professional guidance.

Have you or a loved one navigated the complexities of fertility preservation? Share your thoughts or questions in the comments below, or subscribe to our health insights newsletter for the latest updates on reproductive medicine and patient advocacy.

June 3, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Common Anemia Drugs May Slow Cancer Growth

by Chief Editor May 28, 2026
written by Chief Editor

A Dual-Action Future: Could Anemia Drugs Transform Cancer Treatment?

For cancer patients, managing the disease often feels like a balancing act. Between the aggressive nature of tumors and the debilitating side effects of chemotherapy, patients frequently battle a secondary, yet equally taxing, condition: anemia. Now, groundbreaking research suggests that a class of medications already used to treat anemia in kidney disease patients might hold the key to a more integrated approach to cancer care.

View this post on Instagram about University of Oulu
From Instagram — related to University of Oulu

Researchers from the University of Oulu and the University of Eastern Finland have uncovered evidence that HIF-PHIs—drugs typically prescribed to boost red blood cell production—may possess an unexpected secondary function: the ability to inhibit the growth of cancer cells and restrict the formation of new blood vessels that tumors need to survive.

Did you know?

HIF-PHIs work by stabilizing proteins that help cells respond to low oxygen levels. Researchers found that even when these specific proteins are absent, the drugs can still interfere with cell metabolism and slow down tumor progression.

Shifting the Paradigm of Tumor Management

Historically, treating cancer and managing chemotherapy-induced anemia have been treated as distinct clinical objectives. Oncologists often address the tumor through chemotherapy while managing anemia as a reactive measure. This new study, published in the journal Redox Biology, suggests a shift toward a “dual-advantage” strategy.

Shifting the Paradigm of Tumor Management
University of Oulu laboratory

Professor Thomas Kietzmann, leading the team at the Hypoxia and Extracellular Matrix Research Unit at the University of Oulu, notes that the discovery challenges current understandings of how these drugs function. “We expected the drugs to work only through the usual oxygen pathway. Instead, we saw that they could stop cells from growing and prevent new blood vessels from forming on their own,” Kietzmann explains.

The Path to Clinical Application

While the laboratory results are promising, the research team is calling for a collaborative effort to move these findings into clinical trials. Mechanistic data is a vital first step, but the next phase requires the expertise of oncologists and clinicians to determine how these medications can be safely and effectively combined with existing chemotherapy regimens.

University of Oulu Campus Tour: Linnanmaa

The goal is to move beyond the lab and into patient-centered care. By initiating clinical trials, researchers hope to determine if these medications can provide a dual benefit: stabilizing blood counts while simultaneously exerting an anti-tumor effect. This type of interdisciplinary teamwork is essential for evolving how we approach complex, multi-symptom patient care.

Pro Tip:

Stay updated on the latest breakthroughs in oncology by following clinical trial registries. When research moves from the laboratory to human trials, it marks a critical milestone in turning theoretical potential into actual medical treatments.

Frequently Asked Questions (FAQ)

What are HIF-PHIs?
HIF-PHIs are medications currently approved for the treatment of anemia in patients with chronic kidney disease. They help the body produce more red blood cells by stabilizing specific proteins that respond to low oxygen levels.

How could these drugs help cancer patients?
Recent research indicates that these drugs may also inhibit tumor growth and prevent the formation of blood vessels that tumors use to grow, potentially allowing for a more efficient, dual-purpose treatment plan for patients suffering from both cancer and anemia.

Are these drugs currently used to treat cancer?
No. The findings are based on recent laboratory research. The authors of the study are currently seeking clinical partners to validate these results in human clinical trials.

This research was supported by the Research Council of Finland (SA356920 and PROFI6 336449) and the Jane and Aatos Erkko Foundation (210031).


Join the Conversation: What are your thoughts on repurposing existing medications for new therapeutic uses? Share your perspective in the comments below or subscribe to our newsletter for the latest updates on medical research innovations.

May 28, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Yoga Therapy Improves Mental Well-being for Cancer Survivors

by Chief Editor May 26, 2026
written by Chief Editor

Integrative Oncology: Why Gentle Yoga is Changing Survivorship

For millions of people navigating life after a cancer diagnosis, the transition from active treatment to survivorship can be physically and emotionally taxing. Recent clinical research from the Wilmot Cancer Institute highlights a promising, non-drug approach to managing the lingering side effects of surgery and chemotherapy: gentle, restorative yoga.

View this post on Instagram about Cancer Survivors, Wilmot Cancer Institute
From Instagram — related to Cancer Survivors, Wilmot Cancer Institute

The American Society of Clinical Oncology (ASCO) has recognized this research as a significant development in integrative oncology. By focusing on mindfulness and slow-paced movement, this intervention addresses four core domains of patient distress: mood disturbances, anxiety, fatigue, and sleep quality.

Pro Tip: When exploring yoga for symptom management, prioritize classes labeled as “Gentle Hatha” or “Restorative.” Unlike high-intensity styles like Vinyasa or Hot Yoga, these restorative practices focus on mindfulness and breathing rather than vigorous physical exertion.

The Synergy of Mind-Body Movement

The study, led by researchers including Yuri Choi, PhD, and Karen Mustian, PhD, involved a nationwide, randomized, controlled clinical trial of 410 adult cancer survivors. Participants who engaged in four weeks of yoga sessions—three times a week for 180 minutes total—reported significant improvements in their overall well-being compared to those receiving only standard follow-up care.

Dr. Mustian, dean’s professor of Surgery and associate director of Population Science at Wilmot, emphasizes that yoga is more than just stretching. “Just doing downward dog without the breathing and mindfulness is simply calisthenics,” she explains. “It’s the synergy of the mind-body movement that brings positive effects.”

Addressing the Symptom Cycle

One of the most compelling findings is the connection between anxiety, and sleep. Research indicates that when patients experience relief from anxiety through yoga, their sleep quality often improves as a secondary benefit. This is crucial, as chronic sleep issues and fatigue can have long-term implications for heart health among cancer survivors.

What Is Oncology Yoga? 5-Hour Course for Yoga Teachers & Health Professionals | yoga4cancer
Did you know? As of early 2025, there were more than 18 million people in the U.S. Living with a history of cancer. That figure is projected to climb to 22 million by 2035, making the development of accessible, non-pharmacological symptom management tools more critical than ever.

Integrating Wellness into Cancer Care

The shift toward integrative oncology marks a move away from pharmaceutical-only approaches to symptom management. For many survivors, adding more medications to manage side effects like depression or insomnia can lead to complex drug interactions. A drug-free, evidence-based intervention like yoga offers a safer alternative that empowers patients to take an active role in their recovery.

Integrating Wellness into Cancer Care
Yuri Choi Wilmot Cancer Institute

Looking ahead, researchers are focused on expanding these programs to reach diverse populations, including Black and Latino patients, as well as adolescents and young adults. Future studies will also investigate the potential for gentle yoga to influence long-term cancer survival outcomes.

Frequently Asked Questions

  • Is yoga safe for all cancer survivors?
    Patients should always consult with their physicians before beginning any new exercise program to ensure it is appropriate for their specific diagnosis and treatment history.
  • How long does it take to see results?
    According to researchers at Wilmot, participants may see significant improvements in symptoms after just one month of consistent restorative yoga practice.
  • Do I need to be flexible to start?
    No. Gentle and restorative yoga programs are designed to be accessible and do not require prior yoga experience or high levels of physical fitness.

Have you or a loved one used integrative therapies like yoga during cancer recovery? Share your experiences in the comments below or subscribe to our newsletter for the latest updates on cancer survivorship research and wellness strategies.

May 26, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

New Oral Drug Boosts Platelet Recovery in GI Cancer Patients

by Chief Editor May 22, 2026
written by Chief Editor

Breaking Barriers in Cancer Care: Oral Medication Shows Promise for Chemotherapy Side Effects

For patients battling gastrointestinal cancers, the journey through chemotherapy is often interrupted by a common but debilitating obstacle: chemotherapy-induced thrombocytopenia (CIT). This condition, characterized by low blood platelet counts, often forces clinicians to delay or reduce life-saving treatment doses, which can negatively impact overall patient outcomes.

However, recent results from a phase 2 clinical trial offer a glimpse of a more seamless future for cancer treatment. Researchers at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and Mass General Hospital have identified that an oral medication, avatrombopag, may provide a significant breakthrough for those struggling to maintain the platelet counts necessary to stay on schedule with their chemotherapy.

Did you know?

Platelets are vital blood cells that help the body form clots. When counts drop too low due to chemotherapy, patients face a heightened risk of life-threatening bleeding even from minor injuries.

The Power of Oral Treatment Options

Avatrombopag is a thrombopoietin receptor agonist already approved for use in patients with liver disease. In the recent clinical trial, the drug demonstrated remarkable efficacy in helping patients with gastrointestinal cancers recover their platelet levels. Among the trial participants, 65% of those receiving avatrombopag met key treatment goals, compared to just 17% of those in the placebo group.

Gerald A. Soff, M.D., chief of classical hematology at Sylvester, who led the trial, emphasized the importance of these findings. “These are the patients, based on our experience, who have the greatest need and will benefit the most from use of a thrombopoietin receptor agonist,” Soff noted.

One of the most significant advantages of this medication is its oral administration. Currently, many treatments for CIT require frequent trips to an infusion center for injections. For patients already dealing with the physical and emotional burden of metastatic cancer, eliminating the need for weekly travel can significantly improve their quality of life.

“You can imagine if someone is dealing with metastatic cancer and they’re not feeling great, and they’re trying to maintain a life, having to go in every single week for a shot is not ideal,” Soff said. “If there’s a good oral option, that would be very appealing for many people.”

Why Consistency in Chemotherapy Matters

The primary goal of this therapy is to avoid compromising cancer treatment. When platelet counts remain high, patients can receive their chemotherapy as originally scheduled. According to Soff, there is clear evidence that dose reductions or delays can impact cancer outcomes. By stabilizing platelet counts, clinicians hope to keep patients on their intended treatment trajectory without interruption.

Why Consistency in Chemotherapy Matters
Cancer Patients Soff
Pro Tip:

If you or a loved one are experiencing treatment delays due to low blood counts, discuss the latest clinical trial developments with your oncologist. Asking about emerging oral options can be a proactive way to manage your care plan.

Looking Ahead: The Future of CIT Management

While the initial study focused on patients with gastrointestinal cancers to ensure consistent data, researchers believe the benefits could extend to many other tumor types. The trial was so effective that researchers were able to complete their analysis at 23 patients, rather than the original goal of 40. Moving forward, the team is continuing to monitor these patients to understand the long-term benefits of the medication.

Prof Gerald A Soff | Role of Romiplostim in Chemotherapy induced Thrombocytopenia

As the medical community continues to explore thrombopoietin receptor agonists, the shift toward convenient, patient-friendly oral treatments represents a major step forward in supportive oncology care.

Frequently Asked Questions

What is chemotherapy-induced thrombocytopenia (CIT)?

CIT is a common side effect of chemotherapy where the body’s blood platelet count drops, making it challenging for the blood to clot properly and often requiring a delay in cancer treatment.

What is chemotherapy-induced thrombocytopenia (CIT)?
Cancer Patients

Why is an oral medication preferred over injections?

Oral medications allow patients to manage their condition at home, reducing the need for frequent, often difficult travel to clinics or infusion centers for injections.

Is avatrombopag currently approved for CIT?

While avatrombopag is FDA-approved for thrombocytopenia in patients with liver disease, it is not yet approved for CIT. However, recent clinical trials have shown significant promise for this use.


Are you interested in learning more about the latest breakthroughs in cancer supportive care? Subscribe to our newsletter for the latest updates or explore our oncology archives to read more about innovative clinical trials.

May 22, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Cancer-driving MYC protein also helps tumors repair damaged DNA

by Chief Editor May 17, 2026
written by Chief Editor

Breaking the Shield: How Targeting MYC’s DNA Repair Secret Could Revolutionize Cancer Treatment

For decades, the medical community has viewed the MYC protein as a relentless engine of cancer growth. It is one of the most studied oncogenes because it is overactive in the vast majority of human cancers, acting as a master switch that revs up metabolism and cell proliferation.

However, a groundbreaking study from Oregon Health & Science University (OHSU) has revealed that MYC does more than just drive growth—it acts as a survival shield. This discovery shifts our understanding of cancer resistance and opens a new frontier for precision oncology.

Did you know? MYC has long been labeled “undruggable” by scientists because its structure makes it incredibly difficult for traditional drugs to bind to it without harming healthy cells.

The Non-Canonical Role: From Genetic Switch to Repair Crew

Traditionally, scientists believed MYC operated solely within the cell’s nucleus to turn genes on and off. The new research, published in Genes & Development, reveals a “non-canonical” or nontraditional role: when DNA is damaged, a modified form of MYC physically migrates to the site of the break.

View this post on Instagram about Canonical Role, Genetic Switch
From Instagram — related to Canonical Role, Genetic Switch

Once there, it recruits the necessary repair machinery to fix the DNA. While DNA repair is a vital process for healthy cells, it becomes a lethal advantage for tumors. Most standard therapies, such as radiation and chemotherapy, work by inflicting such severe DNA damage that the cancer cell is forced to die.

As Rosalie Sears, Ph.D., senior author and co-director of the OHSU Brenden-Colson Center for Pancreatic Care, explains: “Our work shows that MYC isn’t just helping cancer cells grow – it’s also helping them survive some of the very treatments designed to kill them.”

Future Trend: Precision Inhibition of DNA Repair

The discovery that MYC physically assists in DNA repair provides a more precise target for future drug development. Rather than trying to shut down every function of the MYC protein—which could be toxic to normal cells—researchers are looking for ways to specifically block its repair-related activity.

Future Trend: Precision Inhibition of DNA Repair
Development

This approach could transform how we treat aggressive malignancies. By interfering with MYC’s ability to recruit repair proteins, doctors may be able to “strip” the tumor of its defenses, making it significantly more vulnerable to existing treatments. [Internal link: The Evolution of Targeted Cancer Therapies]

The Impact on Pancreatic Cancer

This trend is particularly promising for pancreatic cancer, one of the deadliest forms of the disease. Gabriel Cohn, Ph.D., first author of the study, notes that tumor cells in these aggressive cancers experience extreme replication stress and DNA damage yet continue to thrive.

The OHSU team found that tumors with high MYC activity showed increased signs of DNA repair and were linked to worse patient outcomes. This suggests that MYC is a primary driver of chemotherapy resistance in these patients.

Pro Tip for Patients and Caregivers: When discussing treatment options for aggressive cancers, ask your oncology team about “biomarker testing.” Understanding the activity levels of proteins like MYC can eventually help determine which targeted therapies or clinical trials are most appropriate.

The Rise of “Window of Opportunity” Trials

We are moving toward a future where the efficacy of a drug is measured in real-time within the patient’s own tumor. OHSU is already pioneering this through a “window of opportunity” trial.

The Rise of "Window of Opportunity" Trials
Future Trend

In these short-term studies, patients with advanced pancreatic cancer undergo biopsies both before and after receiving a first-in-class MYC inhibitor called OMO-103. This allows researchers to see exactly how blocking MYC affects the tumor environment in real human patients, rather than relying solely on lab models.

This trend toward rapid, biopsy-driven feedback loops will likely become the gold standard for developing inhibitors for other “undruggable” proteins.

Synergistic Therapy: The Next Frontier

The most significant future trend emerging from this research is the potential for synergistic combination therapies. If MYC is the “shield” that protects the cancer from chemotherapy, the most effective strategy may be a two-pronged attack:

  • Step 1: Administer a MYC inhibitor (like OMO-103) to disable the cell’s DNA repair mechanism.
  • Step 2: Apply chemotherapy or radiation to inflict DNA damage that the cell can no longer fix.

This strategy could potentially lower the doses of toxic chemotherapy required while increasing the overall kill rate of the tumor cells.

Frequently Asked Questions

What is the MYC protein?
MYC is a protein that acts as a transcription factor, meaning it turns genes on to drive cell growth and metabolism. It is overactive in most human cancers.

Why does MYC make cancer harder to treat?
Beyond driving growth, MYC helps repair dangerous breaks in the DNA of tumor cells. This allows cancer cells to survive chemotherapy and radiation, which rely on damaging DNA to kill the tumor.

Is there a drug that targets MYC?
While MYC was long considered “undruggable,” researchers are currently testing a first-in-class inhibitor called OMO-103 in clinical trials at OHSU.

Which cancers are most affected by this?
While MYC is found in most cancers, these findings are especially relevant for aggressive types like pancreatic cancer, where MYC activity is often very high.

For more detailed scientific data, you can explore the full study in Genes & Development.

Join the Conversation

Do you think precision inhibitors are the key to overcoming chemotherapy resistance? Share your thoughts in the comments below or subscribe to our newsletter for the latest breakthroughs in oncology.

Subscribe for Updates

May 17, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma

by Chief Editor May 14, 2026
written by Chief Editor

Breaking the Deadlock: The New Frontier in Glioblastoma Treatment

For more than twenty years, the standard of care for glioblastoma—the most common and aggressive primary brain cancer in adults—has remained largely stagnant. Despite the combined efforts of surgery, radiation, and chemotherapy, this disease remains uniformly fatal, often recurring rapidly after treatment. However, recent preclinical research is signaling a paradigm shift in how we approach these deadly tumors.

Researchers at McMaster University have developed a next-generation immunotherapy that doesn’t just target the cancer cells themselves, but dismantles the extremely system that allows the tumor to survive, and grow. This approach represents a broader trend in oncology: moving away from “one-size-fits-all” chemotherapy toward precision-engineered immune responses.

Did you know? Glioblastoma is notoriously difficult to treat because it typically resists standard therapies, with a median survival rate of less than 15 months from the time of diagnosis.

The Power of uPAR: Targeting the Tumor’s Infrastructure

The breakthrough centers on a drug candidate known as a uPAR Chimeric CAR T cell. Unlike traditional treatments, this immunotherapy reprograms the patient’s own immune system to recognize and attack a specific protein called the urokinase receptor, or uPAR.

What makes this specific target so promising is that uPAR is found not only on the surface of glioblastoma cells but also on the nearby support cells that fuel tumor growth. By targeting uPAR, the therapy achieves a dual objective:

  • Direct Elimination: It identifies and destroys the deadly cancer cells.
  • Infrastructure Collapse: It dismantles the biological infrastructure that glioblastoma uses to persist and recur after treatment.

This “dual-action” strategy is a key trend in modern cancer research. Rather than focusing solely on the malignant cell, scientists are now targeting the tumor microenvironment—the surrounding ecosystem that protects the cancer from the immune system and provides it with nutrients.

A Collaborative Blueprint for Success

This advancement wasn’t achieved in isolation. The therapy was developed using antibodies created through a partnership with scientists at Canada’s National Research Council in Ottawa. This highlights a growing trend in medical science: the convergence of academic research and national scientific institutions to accelerate the path from the lab to the clinic.

For those following immunotherapy developments, the transition of CAR T cell therapy from blood cancers to solid tumors like glioblastoma is one of the most anticipated shifts in oncology.

Pro Tip: When reading about “preclinical” results, remember that this means the therapy has shown success in laboratory settings and animal models. The next critical step is “first-in-human” studies to ensure safety and efficacy in patients.

Beyond the Brain: A Universal Target for Hard-to-Treat Cancers?

Perhaps the most exciting implication of this research is that uPAR may not be limited to brain cancer. Sheila Singh, a professor in McMaster’s Department of Surgery and principal investigator of the study, notes that this work is part of a wider shift in the field.

Duke researchers' pancreatic cancer treatment shows early promise

Evidence from institutions like Columbia University and the Memorial Sloan Kettering Cancer Center suggests that uPAR is also a promising drug target for lung and pancreatic cancers. This suggests a future where a single protein target could lead to a suite of therapies effective across multiple, traditionally “untreatable” cancers.

This trend toward “cross-cancer” targets could drastically streamline drug development, allowing researchers to apply lessons learned in neuro-oncology to other forms of aggressive malignancy.

The Road to Clinical Trials

The transition from a lab discovery to a tangible treatment is a rigorous process. The McMaster team has already patented the therapy and is exploring commercial and clinical pathways. Discussions regarding the move toward clinical trials are already underway, driven by the urgent need for alternatives to the current standard of care.

As William Maich, a postdoctoral fellow at McMaster and first author on the study, emphasizes, the motivation behind this work is the human element—the desire to provide patients and their families with a viable alternative to a disease that has long felt inevitable.

Frequently Asked Questions

What is a uPAR Chimeric CAR T cell?
It is an immunotherapy that reprograms the body’s immune system to attack the urokinase receptor (uPAR), a protein found on glioblastoma cells and their supporting infrastructure.

Why is glioblastoma so hard to treat?
It is the most aggressive type of primary brain cancer in adults and typically resists standard treatments like surgery, radiation, and chemotherapy, often recurring quickly.

Is this treatment available to patients now?
No. The research is currently in the preclinical stage. Researchers are working toward translating these results into first-in-human clinical trials.

Could this therapy work for other types of cancer?
Yes, there is potential. Researchers have identified uPAR as a promising target in other hard-to-treat cancers, including pancreatic and lung cancers.

To learn more about the latest breakthroughs in oncology, explore our comprehensive guide to emerging cancer therapies.

Join the Conversation: Do you think precision immunotherapy will eventually replace traditional chemotherapy? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates in medical science.
May 14, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Lithuanian President: Now Is Not the Time for Talks With Russia

    June 19, 2026
  • The Biggest Threat to Microsoft’s Gaming Ambitions: Steam and AMD

    June 19, 2026
  • 1 Dead, Nearly 90 Injured in London Train Collision

    June 19, 2026
  • Teen Wins Canada’s Top Science Prize for Universe Theory

    June 19, 2026
  • Dasco Calls Bahlil to Address Student Fuel Concerns

    June 19, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World